New scan aims to catch kidney cancer spread that others miss
NCT ID NCT07624578
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study planned to test a special PET-CT scan (68Ga-PSMA) in people newly diagnosed with advanced kidney cancer. The goal was to see if it could find small cancer spots that standard scans miss. However, the trial was withdrawn before any patients were enrolled, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 68Ga-PSMA PET-CT scan
- What this could lead to
- If successful, this scan could help doctors find small cancer spots earlier, leading to more timely treatment.
- What could go wrong
- This trial was withdrawn before it started, so no results are available. The scan is still experimental and may not prove better than current methods.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY CANCERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict who needs extra therapy after kidney cancer surgery?
- Can a Two-Drug combo outsmart advanced cancers?
- Can a rapid drug switch outsmart advanced kidney cancer?
- Can a new nucleotide analogue boost cancer treatment?
- Can a blast of radiation make immunotherapy work better against kidney cancer?
- Can reprogrammed immune cells take on hard-to-treat kidney cancer?